Low-dose vaccinia virus-mediated cytokine gene therapy of glioma

Journal of Immunotherapy

Volumn 24, Issue 1, 2001, Pages 46-57

  Chen, B ^a   Timiryasova, T M ^a   Haghighat, P ^a   Andres, M L ^a   Kajioka, E H ^a   Dutta Roy, R ^a   Gridley, D S ^a   Fodor, I ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer immunotherapy; Glioma; Interleukin 12; Interleukin 2; Vaccinia virus

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GLIOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS ATTENUATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE THERAPY; GENETIC VECTORS; GLIOMA; INJECTIONS, INTRALESIONAL; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, NUDE; ORGAN SPECIFICITY; RATS; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 0035139013     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200101000-00006     Document Type: Article

References (50)

1. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
2. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin-12
3. Recombinant vaccinia expressing interleukin-2 for cancer gene therapy
4. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
5. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
6. Acquired immunity in nude mice induced by expression of the IL-2 or IL- 4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus
7. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors
8. + T cells in the tumor and blood is associated with efficient local IL- 12 gene therapy of cancer
9. Vaccinia virus expression vectors
10. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
11. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta
12. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses
13. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy
14. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model
15. A key cytokine in immune regulation
16. Mechanism of interleukin-12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocorticoids
17. B7-1 and interleukin-12 synergistically induce effective antitumor immunity
18. Cancer trial of interleukin-12 halted
19. Gene gunmediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: A direct comparison with systemic IL-12 therapy
20. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells
21. Expression of cytokines by recombinant vaccinia viruses: A model for studying cytokines in virus infections in vivo
22. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice
23. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy
24. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype
25. Cytokine gene therapy or infusion as treatment of solid human cancer
26. Intravesical gene therapy: In vivo gene transfer using recombinant vaccinia virus vectors
27. Verification of the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment in volunteers
28. Analysis of expression of the reporter genes in different regions of vaccinia virus genome
29. Live recombinant vaccines for humans
30. Antitumor effect of vaccinia virus in glioma model
31. Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy
32. Characterization of angiogenesis and microcirculation of high-grade glioma: An intravital multifluorescence microscopic approach in the athymic nude mouse
33. Animal models for brain tumors: Historical perspectives and future detections
34. Depressed T lymphocyte function in brain tumor patients: Monocytes as suppressor cells
35. Motogen stimulation of blood lymphocytes from patients with primary intracranial tumors. Correlation to histologic tumor type
36. Expression of TGF-beta 2 in human glioblastoma: A role in resistance to immune reaction
37. Differentiated rat glial cell strain in tissue culture
38. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection
39. Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2
40. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression
41. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role
42. Requirement for V-alpha 14 NKT cells in IL-12-mediated rejection of tumors
43. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
44. Interleukin 12: Newest member of the antiangiogenesis club
45. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production
46. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12
47. Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumoricidal activity
48. Newcastle disease virus selectively kills human tumor cells
49. Viruses in the treatment of cancer
50. Experimental therapy of human glioma by means of a genetically engineered virus mutant